The Company intends to convene an Extraordinary General Meeting where the Nomination Committee proposes that Ulf Ericsson be elected as a new Board member.

"The Inhalation Science's Board is very excited about the nomination of Ulf as a new Board member in the company. Given Ulf's long experience and deep understanding of the inhalation research market as well as good insights into the needs and requirements of our customers, he will be instrumental for continuing our commercial expansion. The company's main priorities are still focused on increasing sales, reaching profitability in the business, and continuing to deliver high quality services to our customers. Ulf's role will be important in further strengthening our commercial positioning and outreach together with the Inhalation Sciences Board." says Daniel Spasic, Chairman of the Board of Inhalation Sciences.

Ulf Ericsson (born 1966) has 28 years of experience in Life Science, specializing in pharmaceuticals, inhalers, and inhalation formulations, with a special focus on strategy and business development. For over twenty years, Ulf has worked in the field of inhalation, mostly at AstraZeneca in senior positions with global responsibility. Ulf is currently an independent consultant in business development and strategy within Life Science. Ulf is independent from the Company, the company's management, and major shareholders.  

"I look forward to contributing to Inhalation Sciences' future development and growth, and to leveraging my experience in Life Science and my passion for innovative solutions in the development of inhalation medicines. I believe Inhalation Sciences is a very exciting company developing important technologies and world-class services", says Ulf Ericsson.

The notice of the Extraordinary General Meeting will be published through a separate press release.